EA033304B1 - Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента - Google Patents
Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиентаInfo
- Publication number
- EA033304B1 EA033304B1 EA201691570A EA201691570A EA033304B1 EA 033304 B1 EA033304 B1 EA 033304B1 EA 201691570 A EA201691570 A EA 201691570A EA 201691570 A EA201691570 A EA 201691570A EA 033304 B1 EA033304 B1 EA 033304B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- axl
- pharmaceutical composition
- cancer
- another embodiment
- active ingredient
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 title abstract 2
- -1 heterocyclic carboxamide compound Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 230000004913 activation Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691570A1 EA201691570A1 (ru) | 2016-11-30 |
| EA033304B1 true EA033304B1 (ru) | 2019-09-30 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691570A EA033304B1 (ru) | 2014-02-04 | 2015-02-03 | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (zh) |
| EP (1) | EP3103453B1 (zh) |
| JP (1) | JP6390626B2 (zh) |
| KR (1) | KR102322338B1 (zh) |
| CN (3) | CN116509866A (zh) |
| AU (1) | AU2015215578B2 (zh) |
| BR (1) | BR112016017897A8 (zh) |
| CA (1) | CA2938818C (zh) |
| CY (1) | CY1122968T1 (zh) |
| DK (1) | DK3103453T3 (zh) |
| EA (1) | EA033304B1 (zh) |
| ES (1) | ES2788390T3 (zh) |
| HR (1) | HRP20200662T1 (zh) |
| HU (1) | HUE049437T2 (zh) |
| IL (1) | IL247077B (zh) |
| LT (1) | LT3103453T (zh) |
| ME (1) | ME03775B (zh) |
| MX (1) | MX363543B (zh) |
| MY (1) | MY193536A (zh) |
| PH (1) | PH12016501527B1 (zh) |
| PL (1) | PL3103453T3 (zh) |
| PT (1) | PT3103453T (zh) |
| RS (1) | RS60150B1 (zh) |
| SG (1) | SG11201606413RA (zh) |
| SI (1) | SI3103453T1 (zh) |
| TW (1) | TWI655945B (zh) |
| UA (1) | UA120607C2 (zh) |
| WO (1) | WO2015119122A1 (zh) |
| ZA (1) | ZA201605379B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3103453B1 (en) * | 2014-02-04 | 2020-04-01 | Astellas Pharma Inc. | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| PL3318259T3 (pl) * | 2015-07-03 | 2023-05-02 | Astellas Pharma Inc. | Stabilna kompozycja farmaceutyczna do podawania doustnego |
| US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010128659A1 (ja) * | 2009-05-08 | 2010-11-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| JP2011515397A (ja) * | 2008-03-19 | 2011-05-19 | ケムブリッジ・コーポレーション | 新規チロシンキナーゼ阻害剤 |
| WO2013040801A1 (zh) * | 2011-09-19 | 2013-03-28 | 广州盈升生物科技有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110110923A1 (en) * | 2008-02-12 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| CA2856411A1 (en) * | 2011-11-21 | 2013-05-30 | Immunogen, Inc. | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| UA113204C2 (xx) | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| EP3103453B1 (en) * | 2014-02-04 | 2020-04-01 | Astellas Pharma Inc. | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| PL3318259T3 (pl) * | 2015-07-03 | 2023-05-02 | Astellas Pharma Inc. | Stabilna kompozycja farmaceutyczna do podawania doustnego |
-
2015
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active IP Right Grant
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt active IP Right Grant
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527B1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-24 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011515397A (ja) * | 2008-03-19 | 2011-05-19 | ケムブリッジ・コーポレーション | 新規チロシンキナーゼ阻害剤 |
| WO2010128659A1 (ja) * | 2009-05-08 | 2010-11-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| WO2013040801A1 (zh) * | 2011-09-19 | 2013-03-28 | 广州盈升生物科技有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| BYERS L.A. et al., An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res., 2013, Vol.19, No. l, p.279-290, Table 1 * |
| MOLLARD A. et al., Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors, ACS Med. Chem. Lett., 2011, Vol.2, No. 12, p.907-912, Figure 5. * |
| YAKES F.M. et al., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer. Ther., 2011, Vol.10, No.12, p.2298-2308, Table 1. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA033304B1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
| PH12016500871A1 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| TW201613901A (en) | New compounds | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2017009608A (es) | Compuestos anticancerigenos. | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| IN2013MU03118A (zh) | ||
| MX2017008879A (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| MX2020002812A (es) | Abx196 para usarse en el tratamiento del cancer de vejiga. | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. | |
| MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
| TH169730B (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารประกอบ ไดอะมิโนเฮเทอโรไซคลิกคาร์บอกซาไมด์ดังส่วน ผสมออกฤทธิ์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TM |